Familial and recurrent forms of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura

Contributions to Nephrology

Volumn 136, Issue , 2001, Pages 125-139

  Noris, Marina ^a,b   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H, HUMAN; VON WILLEBRAND FACTOR;

GENETICS; HEMOLYTIC UREMIC SYNDROME; HUMAN; LEUKOCYTE; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; RECURRENT DISEASE; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM;

COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM, VASCULAR; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LEUKOCYTES; MUTATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; VON WILLEBRAND FACTOR;

EID: 0035537917     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (54)

1. Remuzzi G, Ruggenenti P, Bertani T: Thrombotic microangiopathies; inTisher CC, Brenner BM (eds): Renal Pathology. With Clinical and Functional Correlations. Philadelphia, Lippincott, 1994, p 1154.
2. George JN: How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-1229.
3. Bell WR, Braine HG, Ness PM, Kickler TS: Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325:398-403.
4. Kaplan BS, Kaplan P: Hemolytic uremic syndrome in families; in Kaplan BS, Trompeter RS, Moake JL (eds): Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York, Dekker, 1992, p 213.
5. Ruggenenti P, Galbusera M, Plata Cornejo R, Bellavita P, Remuzzi G: Thrombotic thrombo-cytopenic purpura: Evidence that infusion rather than removal of plasma induces remission of the disease. Am J Kidney Dis 1993;21:314-318.
6. Moake JL, McPherson PD: Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 1989;87:9N-15N.
7. Campbell S, Carre IJ: Fatal hemolytic uraemic syndrome and idiopathic hyperlipaemia in monozygotic twins. Arch Dis Child 1965;40:654-658.
8. Kaplan BS, Chesney RW, Drummond KN: Hemolytic uremic syndrome in families. N Engl J Med 1975;292:1090-1093.
9. Berns JS, Kaplan BS, Mackow RC, Hefter LG: Inherited hemolytic uremic syndrome in adults. Am J Kidney Dis 1992;29:331-334.
10. Carreras L, Romero R, Requesens C: Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3, B7 haplotype. JAMA 1981;245:602-604.
11. Noris M, Ruggenenti P, Perna A, Orisio S, Caprioli J, Skerka C, Vasile B, Zipfel PF, Remuzzi G: Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999;10:281-293.
12. Warwicker P, Goodship THJ, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836-844.
13. Petermann A, Offermann G, Distler A, Sharma AM: Familial hemolytic-uremic syndrome in three generations. Am J Kidney Dis 1998;32:1063-1067.
14. Kaplan BS, Papadimitriou M, Brezin JH, Tomlanovich SJ, Zulkharnain M: Renal transplantation in adults with autosomal recessive inheritance of hemolytic uremic syndrome. Am J Kidney Dis 1997;30:760-765.
15. Dang CT, Magid MS, Weksler B, Chadburn A, Laurence J: Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood 1999;93:1264-1270.
16. Mitra D, Jaffe E A, Weksler B, Hajjar KA, Soderland C, Laurence J: Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997;89:1224-1234.
17. Ruiz Torres MP, Casiraghi F, Macconi D, Noris M, Galbusera M, Remuzzi G: Neutrophil (PMNs)-derived toxic products mediate endothelial damage and thrombus formation in recurrent hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (abstract). J Am Soc Nephrol 2000;11:596.
18. Bitzan MM, Wang Y, Lin J, Marsden PA: Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998;101:372-382.
19. Forsyth KD, Simpson AC, Fitzpatrick MM, Barratt TM, Levinsky RJ: Neutrophil-mediated endothelial injury in hemolytic uremic syndrome. Lancet 1989;ii:411-414.
20. Noris M, Ruggenenti P, Todeschini M, Figliuzzi M, Macconi D, Zoja C, Paris S, Gaspari F, Remuzzi G: Increased nitric oxide formation in recurrent thrombotic microangiopathies: A possible mediator of microvascular injury. Am J Kidney Dis 1996;27:790-796.
21. Stuhlinger W, Kourilsky O, Kanfer A, Sraer JD: Haemolytic-uraemic syndrome: Evidence for intravascular C3 activation. Lancet 1974;ii:788-789.
22. Monnens L, Malenaar J, Lambert PH, Proesmans W, van Munster P: The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980;13:168-171.
23. Garvey MB, Freedman J: Complement in thrombotic thrombocytopenic purpura. Am J Hematol 1983;15:397-398.
24. Hammar SP, Bloomer HA, McCloskey D: Adult hemolytic uremic syndrome with renal arteriolar deposition of IgM and C3. Am J Clin Pathol 1978;70:434-439.
25. Sahu A, Lambris JD: Complement inhibitors: A resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 2000;49:133-148.
26. Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989;264:9053-9060.
27. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A: The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997;185:1619-1627.
28. Hardy MM, Flickinger AG, Riley DP, Weiss RH, Ryan US: Superoxide dismutase mimetics inhibit neutrophil-mediated human aortic endothelial cell injury in vitro. J Biol Chem 1994;269:18535-18540.
29. Moake JL: Moschcowitz, multimers, and metalloprotease. N Engl J Med 1998;339:1629-1631.
30. Weinstein MJ, Blanchard R, Moake JL, Vosburgh E, Moise K: Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura. Br J Hematol 1989;72:68.
31. Mannucci PM, Lombardi R, Castaman G, Dent JA, Lattuada A, Rodeghiero F, Zimmerman TS: Von Willebrand disease 'Vicenza' with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988;71:65.
32. Moake JL: Hemolytic-uremic syndrome: Basic science. Lancet 1994;343:393-397.
33. Remuzzi G, Galbusera M, Salvadori M, Rizzoni G, Paris S, Ruggenenti P: Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int 1996;49:282-286.
34. Galbusera M, Noris M, Rossi C, Orisio S, Caprioli J, Ruggeri ZM, Amadei B, Ruggenenti P, Vasile B, Casari G, Remuzzi G: Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. Blood 1999;94:610-620.
35. Mannucci PM, Lombardi R, Lattuada A, Ruggenenti P, Viganò GL, Barbui T, Remuzzi G: Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood 1989;74:978-983.
36. Tsai HM, Sussman II, Nagel RL: Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994;83:2171-2179.
37. Zipfel PF, Hellwage J, Friese M, Hegasy G, Jokiranta TS, Meri S: Factor H and disease: A complement regulator affects vital body function. Mol Immunol 1999;36:241-248.
38. Thompson RA, Winterborn MH: Hypocomplementaemia due to a genetic deficiency of blH globulin. Clin Exp Immunol 1981;46:110-119.
39. Pichette V, Quérin S, Schürch W, Brun G, Lehner-Netsch G, Delaghe JM: Familial hemolyticuremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994;26:936-941.
40. Rougier N, Kazatchkine MD, Rougier JP, Fremeaux-Bacchi V, Blouin J, Deschenes G, Soto B, Baudouin V, Pautard B, Proesmans W, Weiss E, Weiss L: Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998;9:2318-2326.
41. Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E, Gamba S, Skerka C, Marziliano N, Remuzzi G, Noris M, on behalf of the Italian Registry of Familial and Recurrent HUS/TTP: The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001;12:297-307.
42. Richards A, Buddies MR, Donne RL, Kaplan BS, Kirk E, Yenning MC, Tielemans CL, Goodship JA, Goodship THJ: Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001;68:485-490.
43. Pérez-Caballero D, Gonzàlez-Rubio C, Gallardo ME, Vera M, Lòpez-Trascasa M, Rodrìguez de Cordoba S, Sànchez-Corral P: Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001;68:478-484.
44. Buddies MRH, Donne RL, Richards A, Goodship J, Goodship THJ: Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 2000;66:1721-1722.
45. Sharma AK, Pangburn MK: Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci USA 1996;93:10996-11001.
46. Blackmore TK, Hellwage J, Sadlon TA, Higgs N, Zipfel PF, Ward HM, Gordon DL: Identification of the second heparin-binding domain in human complement factor H. J Immunol 1998;160:3342-3348.
47. Hindmarsh EJ, Marks RM: Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol 1998;160:6128-6136.
48. Rey-Campos J, Rubinstain P, De Cordoba SR: A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF andC4PB. J Exp Med 1988;167:664-669.
49. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrie PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
50. Tsai HM, Lia ECY: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
51. Dent JA, Galbusera M, Ruggeri ZM: Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of constituent subunit. J Clin Invest 1991;88:774-782.
52. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B: Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-3103.
53. Furlan M, Robles R, Solenthaler M, Lammle B: Acquired deficiency of von Willebrand factorcleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839-2846.
54. te Loo DMWM, Levtchenko E, Furlan M, Roosendaal GPM, van den Heuvel LPWJ: Autosomal recessive inheritance of von Willebrand factor-cleaving protease deficiency. Pediatr Nephrol 2000;14:762-765.